Publications 2008
Aalbers AG, ten Kate M, van Grevenstein WM, Hofland LJ, Wiemer EA, Jeekel J, van Eijck CH
A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy.
Eur J Surg Oncol. 2008 Apr;34(4):469-75
de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, van Norden Y, Kusuma A, Smitt PS, Gratama JW
B and T cell imbalances in CSF of patients with Hu-antibody associated PNS.
J Neuroimmunol. 2008 Mar;195(1-2):164-70
de Jong FA, Sparreboom A, Verweij J, Mathijssen RH
Lifestyle habits as a contributor to anti-cancer treatment failure.
Eur J Cancer. 2008 Feb;44(3):374-82
de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, Verweij J
Renal function as a predictor of irinotecan-induced neutropenia.
Clin Pharmacol Ther. 2008 Aug;84(2):254-62
de Wit R
Chemotherapy in hormone-refractory prostate cancer.
BJU Int. 2008 Mar;101 Suppl 2:11-5
de Wit R, van den Bent M, Kirkels W
The management of cerebral metastasis from germ cell cancer; walking the tightrope.
Eur J Cancer. 2008 Aug;44(12):1622-4
Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
Br J Cancer. 2008 Jan 15;98(1):80-5
Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, Klijn JG, Wiemer EA, Martens JW
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6
Foekens JA, Wang Y, Martens JW, Berns EM, Klijn JG
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
Drug Discov Today. 2008 Jun;13(11-12):481-7
Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Clin Pharmacol Ther. 2008 Dec;84(6):704-9
Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ
Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Cytometry B Clin Cytom. 2008 Jul;74(4):211-20
Hamberg P, Verhagen PC, de Wit R
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
Eur J Cancer. 2008 Jun;44(9):1193-7
Heijns JB, van der Burg ME, van Gelder T, Fieren MW, de Bruijn P, van der Gaast A, Loos WJ
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
Cancer Chemother Pharmacol. 2008 Oct;62(5):841-7
Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE
Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer.
J Clin Oncol. 2008 Dec 1;26(34):5561-8
Jager A, Sleijfer S, van der Rijt CC
The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?
Eur J Cancer. 2008 Jan;44(2):175-81
Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Breast Cancer Res Treat. 2009 Jul;116(2):263-71
Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland A, van Geel B, Brekelmans CT, Klijn JG
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Breast Cancer Res Treat. 2008 Sep;111(2):303-11
Kruit WH,
[Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications]
Ned Tijdschr Geneeskd. 2008 Mar 8;152(10):574-6
Lamers CH, van Elzakker P, Luider BA, van Steenbergen SC, Sleijfer S, Debets R, Gratama JW
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
Cancer Gene Ther. 2008 Apr;15(4):268-74
Lamers CH, van Elzakker P, van Steenbergen SC, Sleijfer S, Debets R, Gratama JW
Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield.
Cytotherapy. 2008;10(4):406-16
Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM
TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Breast Cancer Res Treat. 2009 Jan;113(2):253-60
Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
Endocr Relat Cancer. 2008 Mar;15(1):101-11
Rietjens JA, van Zuylen L, van Veluw H, van der Wijk L, van der Heide A, van der Rijt CC
Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation.
J Pain Symptom Manage. 2008 Sep;36(3):228-34
Schutte M, Elstrodt F, Bralten LB, Nagel JH, Duijm E, Hollestelle A, Vuerhard MJ, Wasielewski M, Peeters JK, van der Spek P, Sillevis Smitt PA, French PJ
Exon expression arrays as a tool to identify new cancer genes.
PLoS One. 2008;3(8):e3007
Sebestyén Z, Schooten E, Sals T, Zaldivar I, San José E, Alarcón B, Bobisse S, Rosato A, Szöllosi J, Gratama JW, Willemsen RA, Debets R
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.
J Immunol. 2008 Jun 1;180(11):7736-46
Sleijfer S, van der Graaf WT, Blay JY
Angiogenesis inhibition in non-GIST soft tissue sarcomas.
Oncologist. 2008 Nov;13(11):1193-200
Sleijfer S, Verweij J
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Onkologie. 2008 Feb;31(1-2):6-8
Sleijfer S, Wiemer E
Editorial: the long and winding road to better cancer cell-specific therapies.
Oncologist. 2008 May;13(5):593-5
Sleijfer S, Wiemer E
Dose selection in phase I studies: why we should always go for the top.
J Clin Oncol. 2008 Apr 1;26(10):1576-8
Sleijfer S, Wiemer E, Verweij J
Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.
Nat Clin Pract Oncol. 2008 Feb;5(2):102-11
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW
Subtypes of breast cancer show preferential site of relapse.
Cancer Res. 2008 May 1;68(9):3108-14
Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S
Circulating endothelial cells in oncology: pitfalls and promises.
Br J Cancer. 2008 Jun 3;98(11):1731-5
Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW, Gratama JW
Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage.
Thromb Haemost. 2008 Oct;100(4):642-7
Umar A, Jaremko M, Burgers PC, Luider TM, Foekens JA, Pasa-Tolic L
High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS.
Expert Rev Proteomics. 2008 Jun;5(3):445-55
van Meerten E, van der Gaast A, Looman CW, Tilanus HW, Muller K, Essink-Bot ML
Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):160-6
Veerbeek L, van Zuylen L, Swart SJ, van der Maas PJ, de Vogel-Voogt E, van der Rijt CC, van der Heide A
The effect of the Liverpool Care Pathway for the dying: a multi-centre study.
Palliat Med. 2008 Mar;22(2):145-51
Verweij J
'No risk, no fun': challenges for the oncology phase I clinical trial time-performance.
Eur J Cancer. 2008 Nov;44(17):2600-7
Verweij J
Other endpoints in screening studies for soft tissue sarcomas.
Oncologist. 2008;13 Suppl 2:27-31
Verweij J, Eskens F, de Jonge M
The multi-institutional phase I study: disadvantages without advantages?
J Clin Oncol. 2008 Apr 20;26(12):1915-6
Verweij J, Seynaeve C, Sleijfer S
GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.
Adv Exp Med Biol. 2008;610:144-54
Wasielewski M, Vasen H, Wijnen J, Hooning M, Dooijes D, Tops C, Klijn JG, Meijers-Heijboer H, Schutte M
CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Clin Cancer Res. 2008 Aug 1;14(15):4989-94